Testing for DNA repair status in advanced ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study is collecting tumor samples from women newly diagnosed with advanced ovarian cancer to check for a genetic marker called HRD. HRD testing can help doctors understand which treatments might work best for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older
- You have been diagnosed with high-grade epithelial ovarian cancer (the serous or endometrioid type)
- Your cancer is at an advanced stage (stage III or IV) or has returned for the first time after an earlier diagnosis
- Your hospital will run the HRD test using a specific approved method
- Your clinical and lab records will be available for the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether olaparib and durvalumab given around the time of diagnosis can help people with advanced ovarian cancer. It also strongly focuses on collecting tumor and blood samples to better understand who may benefit.
This study collects tumor samples from people newly diagnosed with advanced ovarian cancer to test for HRD, a genetic feature that may help doctors predict which treatments work best. The goal is to see if HRD testing can guide future treatment decisions for patients like you.
This study looks at how women with advanced ovarian cancer respond to treatments based on whether their tumors have a specific DNA repair problem called homologous recombination deficiency (HRD). It aims to understand which treatments work best for different HRD test results.
This study looks at certain “DNA repair traits” (called homologous recombination phenotype) in people with epithelial ovarian cancer. Results may help researchers better understand who responds to platinum chemotherapy, which is commonly used for this cancer.
This study uses a custom lab test on blood (and tumor tissue) to track ovarian cancer returning and to see how well treatment is working. It may help your care team monitor changes over time, especially after certain surgeries.
This Phase 1 study tests HS-10502 in people with advanced solid tumors that have certain DNA repair problems (HRR or HRD). It may help by finding a safe dose and seeing whether the drug can shrink tumors in cancers that have specific genetic features.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.